News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
163,280 Results
Type
Article (6574)
Company Profile (125)
Press Release (156581)
Section
Business (53589)
Career Advice (336)
Deals (9724)
Drug Delivery (27)
Drug Development (31850)
Employer Resources (66)
FDA (2694)
Job Trends (4113)
News (96029)
Policy (6717)
Tag
Academia (253)
Africa (164)
Alliances (12113)
Alzheimer's disease (325)
Approvals (2674)
Artificial intelligence (29)
Asia (13047)
Australia (1401)
Bankruptcy (60)
Best Places to Work (3084)
Biotechnology (82)
C2C Services and Suppliers (2689)
California (630)
Canada (246)
Cancer (113)
Career advice (287)
Cell therapy (37)
China (70)
Clinical research (25937)
Collaboration (35)
Compensation (37)
Connecticut (22)
COVID-19 (622)
Data (76)
Diabetes (19)
Diagnostics (561)
Diversity, equity & inclusion (19)
Earnings (22095)
Employer resources (57)
Europe (23632)
Events (32211)
Executive appointments (50)
FDA (2738)
Florida (58)
Funding (25)
GLP-1 (186)
Government (687)
Healthcare (2235)
Hotbed/Location (119070)
Illinois (26)
Indiana (36)
Infectious disease (626)
Inflammatory bowel disease (35)
Interviews (54)
IPO (5662)
Job creations (1019)
Job search strategy (252)
Kansas (43)
Layoffs (109)
Legal (895)
Liver cancer (19)
Lung cancer (21)
Management (20)
Manufacturing (31)
Maryland (98)
Massachusetts (594)
Medical device (435)
Medtech (436)
Mergers & acquisitions (4063)
Metabolic disorders (66)
Michigan (23)
Minnesota (31)
Neuroscience (366)
New Jersey (240)
New York (281)
NextGen Class of 2024 (966)
Non-profit (233)
North Carolina (231)
Northern California (288)
Now hiring (22)
Obesity (36)
Ohio (39)
Opinion (65)
Patents (23)
Pennsylvania (158)
People (16629)
Pharmaceutical (40)
Phase I (7811)
Phase II (11964)
Phase III (8742)
Pipeline (45)
Podcasts (31)
Policy (28)
Postmarket research (510)
Preclinical (2916)
Press Release (19)
Rare diseases (30)
Real estate (1193)
Recruiting (27)
Regulatory (5374)
Research institute (279)
Resumes & cover letters (40)
South America (208)
Southern California (271)
Startups (954)
Texas (61)
United States (2706)
Vaccines (86)
Washington State (58)
Weight loss (25)
Date
Last 7 days (230)
Last 30 days (693)
Last 365 days (13473)
2024 (9022)
2023 (14344)
2022 (16202)
2021 (17844)
2020 (15214)
2019 (10001)
2018 (7150)
2017 (8951)
2016 (7309)
2015 (9302)
2014 (7062)
2013 (5085)
2012 (4915)
2011 (4844)
2010 (4810)
163,280 Results for "arbutus biopharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Arbutus to Participate in Jefferies Global Healthcare Conference
Arbutus Biopharma Corporation today announced that the Arbutus management team will present at and host one-on-one meetings at the following upcoming investor conference being held in New York.
May 29, 2024
·
1 min read
Policy
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
Arbutus Biopharma Corporation today issued the following statement regarding the claim construction ruling of the U.S. District Court for the District of Delaware in the lawsuit brought by Arbutus and its licensee Genevant Sciences (Plaintiffs) against Moderna.
April 4, 2024
·
5 min read
Pharm Country
Arbutus to Participate in Two Upcoming May 2024 Investor Conferences
Arbutus Biopharma Corporation announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York.
May 7, 2024
·
1 min read
Pharm Country
Arbutus to Present Imdusiran Data at EASL Congress 2024
Arbutus Biopharma Corporation announced that two abstracts have been accepted for poster and oral presentations at the European Association for the Study of the Liver Congress 2024 taking place June 5 - 8, 2024 in Milan, Italy.
May 22, 2024
·
6 min read
Business
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation today reports first quarter 2024 financial results and provides a corporate update.
May 2, 2024
·
17 min read
Pharm Country
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Arbutus Biopharma Corporation announced new preliminary end-of-treatment data from the Phase 2a clinical trial in patients receiving ongoing standard-of-care nucleoside analogue therapy indicating that treatment with imdusiran, Arbutus’ RNAi therapeutic, followed by Barinthus Biotherapeutic’s T-cell stimulating immunotherapeutic, VTP-300, was generally safe, well-tolerated and led to maintenance of lower HBsAg levels during the post-treatment follow-up period in patients with cHBV.
June 6, 2024
·
9 min read
Business
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
Arbutus Biopharma Corporation , today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 2024.
April 18, 2024
·
1 min read
Pharm Country
Arbutus to Participate in Two Upcoming Investor Conferences - March 8, 2024
Arbutus Biopharma Corporation today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL.
March 8, 2024
·
1 min read
Business
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
Arbutus Biopharma Corporation today announced that after a distinguished 38-year career, the Company’s co-founder and Chief Scientific Officer, Dr. Michael Sofia, will retire effective December 31, 2024.
May 2, 2024
·
5 min read
Press Releases
Arbutus to Participate in Two Upcoming Investor Conferences
September 3, 2024
·
1 min read
1 of 16,328
Next